Investor Relations

Latest Financial Results

Feb 20, 2024 • 4:05 PM EST

FY 2023 Year End Results

Fiscal Year Ended Dec 31, 2023

Company Overview

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma
Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. 

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Stock Snapshot

IR Contacts

Headquarters

NeoGenomics, Inc.
9490 NeoGenomics Way
Fort Myers, FL 33912
T: 239-768-0600
F: 239-690-4237

Investor Relations

Kendra Sweeney
Investor Relations and ESG
T: 239-877-7474
Kendra.sweeney@neogenomics.com

Transfer Agent

Broadridge Shareholder Services
1155 Long Island Avenue
Edgewood, NY 11717-8309
T: (888) 789-8606